Efalizumab

What is Efalizumab?

Efalizumab was a recombinant humanized IgG1 monoclonal antibody designed to treat moderate to severe chronic plaque psoriasis in adults who were candidates for systemic therapy or phototherapy. Marketed under the brand name Raptiva, Efalizumab worked by targeting the CD11a subunit of lymphocyte function-associated antigen-1 (LFA-1), a protein found on the surface of T-lymphocytes. This action was intended to disrupt the immune processes that drive psoriasis. However, due to significant safety concerns, particularly the risk of serious infections including Progressive Multifocal Leukoencephalopathy (PML), Efalizumab was voluntarily withdrawn from the market in the United States and Europe in 2009.

How Does it Work?

The pathogenesis of psoriasis involves the abnormal activation and proliferation of T-lymphocytes, which then migrate into the skin, leading to inflammation and rapid cell turnover. Efalizumab's mechanism of action focused on inhibiting this T-cell activity. Specifically, Efalizumab binds to the CD11a subunit of LFA-1 on the surface of T-cells. LFA-1 plays a crucial role in several immune processes, including T-cell activation, adhesion, and migration into target tissues. By blocking CD11a, Efalizumab prevented the interaction between LFA-1 on T-cells and its ligand, intercellular adhesion molecule-1 (ICAM-1), found on antigen-presenting cells and endothelial cells. This blockade had several effects:

• It inhibited T-cell activation, reducing the proliferation of T-cells.
• It prevented T-cell adhesion to other cells, thereby interfering with their ability to form immunological synapses.
• It reduced the migration of activated T-cells from the bloodstream into the skin, where they contribute to psoriatic plaques.

By disrupting these key steps in the immune cascade, Efalizumab aimed to reduce the inflammation and hyperproliferation of skin cells characteristic of psoriasis. While effective in many patients, its broad interference with T-cell function also led to the significant immunosuppression that ultimately necessitated its withdrawal.

Medical Uses

Prior to its withdrawal, Efalizumab was approved for the treatment of adult patients with moderate to severe chronic plaque psoriasis who were candidates for systemic therapy or phototherapy. It was typically considered for individuals who had not responded adequately to, or could not tolerate, other systemic treatments. The goal of treatment was to improve the signs and symptoms of psoriasis, such as redness, scaling, and thickness of the skin lesions. Patients receiving Efalizumab often experienced a significant reduction in the Psoriasis Area and Severity Index (PASI) scores, indicating an improvement in their condition. However, it is critical to reiterate that Efalizumab is no longer available for prescription due to the unacceptable risk profile identified during its post-market surveillance.

Dosage

When it was available, Efalizumab was administered via subcutaneous injection. The typical dosage regimen involved a single initial dose of 0.7 mg/kg, followed by weekly maintenance doses of 1.0 mg/kg. The maximum single dose was not to exceed 200 mg. Patients were instructed on how to self-administer the injection. Treatment duration was individualized based on response and tolerability, though long-term use was associated with increased risks. Due to the drug's withdrawal, current information regarding dosage is purely historical and should not be considered for any active treatment decisions. Any patient who was previously on Efalizumab should consult their healthcare provider for alternative treatment strategies.

Side Effects

Efalizumab was associated with a range of side effects, some of which were common and generally manageable, while others were severe and led to its market withdrawal. Common side effects included:

• Headache
• Flu-like symptoms (fever, chills, myalgia)
• Nausea
• Injection site reactions (pain, redness, swelling)

More serious and concerning side effects included:

• Progressive Multifocal Leukoencephalopathy (PML): A rare but often fatal demyelinating disease of the central nervous system caused by the JC virus. Several confirmed cases of PML in patients treated with Efalizumab were reported, leading to its withdrawal.
• Serious Infections: Efalizumab, as an immunosuppressant, increased the risk of bacterial, viral, and fungal infections, including opportunistic infections.
• Malignancies: An increased incidence of various malignancies, including cutaneous and non-cutaneous cancers, was observed in patients treated with Efalizumab.
• Thrombocytopenia: A decrease in platelet count, which could lead to an increased risk of bleeding.
• Hemolytic anemia and pure red cell aplasia.
• Psoriasis exacerbation: Some patients experienced a worsening of their psoriasis, sometimes severe, upon discontinuation of the drug.

The severity of these risks, particularly PML, significantly outweighed the benefits for many patients, leading regulatory agencies and the manufacturer to conclude that the drug's risks were no longer acceptable.

Drug Interactions

Given its immunosuppressive properties, Efalizumab had several important drug interactions. Concomitant use with other immunosuppressive agents, such as cyclosporine, methotrexate, or corticosteroids, could further increase the risk of serious infections. Patients receiving Efalizumab were generally advised against receiving live vaccines, as the immunosuppressive effect of Efalizumab could reduce the immune response to the vaccine or, in rare cases, lead to vaccine-associated infection. It was also important to monitor for potential interactions with medications that could affect platelet count or function, due to the risk of thrombocytopenia associated with Efalizumab. Healthcare providers needed to carefully assess a patient's entire medication regimen to minimize risks when Efalizumab was in use.

FAQ

Q1: Is Efalizumab still available for psoriasis treatment?

No, Efalizumab (Raptiva) was voluntarily withdrawn from the market in 2009 due to an unacceptable risk of serious adverse events, particularly Progressive Multifocal Leukoencephalopathy (PML).

Q2: What was Efalizumab primarily used for?

Efalizumab was used to treat adult patients with moderate to severe chronic plaque psoriasis who were candidates for systemic therapy or phototherapy.

Q3: How was Efalizumab administered?

Efalizumab was administered as a subcutaneous injection, typically once weekly after an initial loading dose.

Q4: What were the main safety concerns associated with Efalizumab?

The most significant safety concerns included Progressive Multifocal Leukoencephalopathy (PML), an increased risk of serious infections, and an increased risk of malignancies.

Q5: Are there alternative treatments for psoriasis now that Efalizumab is withdrawn?

Yes, there are numerous effective alternative treatments for moderate to severe psoriasis, including other biologics (e.g., TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors), small molecule inhibitors, and traditional systemic therapies.

Products containing Efalizumab are available through trusted online pharmacies. You can browse Efalizumab-based medications at ShipperVIP or Medicenter.

Summary

Efalizumab, marketed as Raptiva, was a humanized monoclonal antibody once used for the treatment of moderate to severe chronic plaque psoriasis. Its mechanism involved targeting the CD11a subunit of LFA-1 on T-cells, thereby inhibiting T-cell activation, adhesion, and migration, which are crucial processes in the pathology of psoriasis. While demonstrating efficacy in improving psoriatic symptoms, Efalizumab was associated with a significant risk of severe side effects, most notably Progressive Multifocal Leukoencephalopathy (PML), a rare but often fatal brain infection. Due to these serious safety concerns, Efalizumab was voluntarily withdrawn from global markets in 2009. Its history serves as a critical reminder of the complex risk-benefit assessments involved in pharmaceutical development and the importance of ongoing pharmacovigilance for all medications.